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Abstract
The predictive value of plasma protein C level in sepsis has been
demonstrated in a number of studies in which depressed protein C
levels were associated with increased likelihood of negative
outcome. Data from the PROWESS (Recombinant Human
Activated Protein C Worldwide Evaluation in Severe Sepsis) trial
indicate that administration of drotrecogin alfa (activated; DrotAA)
leads to an increase in endogenous protein C levels in severe
sepsis patients. In a group as heterogeneous as sepsis patients,
the currently approved dose and duration of administration
(24 μg/kg per hour for 96 hours) might not be optimal in some
individuals. The RESPOND (Research Evaluating Serial Protein C
levels in severe sepsis patients ON Drotrecogin alfa [activated])
trial is a phase II study being conducted to explore the use of
endogenous protein C level as both a biomarker and a steering
parameter for administration of DrotAA. Eligible patients will
receive DrotAA either at the normal, currently approved dose and
duration of administration (‘standard therapy’) or at a higher dose
with variable infusion duration or variable infusion duration only
(‘alternative therapy’). The duration of DrotAA infusion in the
alternative therapy arm depends on the individual response in
terms of sustained increase in endogenous protein C. The ultimate
aims of this and potential following studies are as follows: to
establish serial plasma protein C measurement as a biomarker that
will aid in the identification of severe sepsis patients who are most
likely to benefit from DrotAA therapy, to enable adjustment of
DrotAA therapy in individual patients (specifically, the possibility to
use a higher dose and to adjust the infusion duration), and to
provide guidance to the clinician regarding whether the patient is
responding to DrotAA.
Introduction
That there is an association between sepsis and activation of
the coagulation system has been known for nearly 40 years
[1]. Microbial toxins and inflammatory cytokines released into
the systemic circulation initiate a cascade of events that
results in widespread inflammation, endothelial injury and
microvascular thrombosis [2,3]. Endogenous protein C, a
vitamin K dependent glycoprotein that is synthesized by the
liver, plays an important role in the maintenance of haemo-
stasis and modulation of inflammation under normal
conditions [4,5]. Protein C circulates in the blood in zymogen
form (inactivated form) at a concentration of approximately
4 μg/ml. Currently, various methods, reagents and equipment
exist to measure protein C in the laboratory or even at the
bedside in the intensive care unit (ICU). In general, these
methods can be subdivided into those that are based on
measuring the functional activity of the protein (%) and
antigenic methods, which measure the amount of protein
available (μg/ml).
Protein C is converted to activated protein C (APC) by
thrombin-thrombomodulin complexes. APC inactivates
coagulation factors Va and VIIIa, thereby inhibiting further
thrombin generation. Moreover, by inhibiting plasminogen
activator inhibitor-1, APC is indirectly profibrinolytic. In
addition to its role as an anticoagulant, a number of anti-
inflammatory effects and anti-apoptotic properties have been
described [6]. Recent research indicates that inhibition of
neutrophil chemotaxis and a role in maintaining endothelial
integrity are other important effects of APC. Direct
cytoprotective effects of APC have been reported to be
mediated by intracellular signalling, initiated by binding of
APC to its receptor (the endothelial protein C receptor),
which appears to be mediated by interaction with an adjacent
protease-activated receptor or by indirect activation of the
sphingosine 1-phosphate pathway [7,8].
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Protein C is rapidly depleted in severe sepsis because of
consumption, degradation by elastase and a reduced synthe-
sis by the liver. With the reduction in protein C zymogen, the
hypercoagulable condition and hyper-inflammatory response
in sepsis is not counterbalanced, which leads to organ dys-
function and death in approximately 20% to 40% of cases.
Drotrecogin alfa (activated; DrotAA) is a recombinant version
of endogenous human APC. The PROWESS (Recombinant
Human Activated Protein C Worldwide Evaluation in Severe
Sepsis) trial established that DrotAA (Xigris®, Eli Lilly and
Company, Indianapolis, IN, USA) is an effective treatment for
adult patients with severe sepsis when it is infused at
24 μg/kg per hour for 96 hours [9], which is the currently
licensed regimen. Thus far, the compound has been
evaluated in more than 9,000 patients enrolled in clinical
trials. Studies have considered the following issues: safety
(ENHANCE [Extended Evaluation of Recombinant Human
Activated Protein C, drotrecogin alfa (activated)] study [10]),
use in patients who are less severely ill than the licensed
indication (ADDRESS [Administration of Drotrecogin Alfa
(Activated) in Early Stage Severe Sepsis] study [11]),
paediatric use (RESOLVE [Researching severe Sepsis and
Organ dysfunction in children: a global perspective] study
[12]), interaction with prophylactic heparin (XPRESS [Xigris
and Prophylactic Heparin Evaluation in Severe Sepsis] study
[13]), and prolonged administration (EXTEND [Efficacy and
Safety of Extended Drotrecogin Alfa (Activated) Therapy in
Patients With Persistent Requirement for Vasopressor
Support After 96 Hour Infusion With Commercial Drotreco-
gin Alfa (Activated)] [14]).
No biomarker has yet been established that can guide the
clinical use of DrotAA. The identification of severe sepsis
patients most likely to benefit from this drug is based mainly
on clinical parameters. The phase II study RESPOND
(Research Evaluating Serial Protein C levels in severe sepsis
patients ON Drotrecogin alfa [activated]) [15] aims to
evaluate the use of endogenous protein C level as a
biomarker to guide treatment with DrotAA.
Protein C as a biomarker
Abnormalities in coagulation parameters are commonly
observed in patients with severe sepsis and have been
associated with higher mortality. These include reductions of
the major natural anticoagulants antithrombin III, tissue factor
pathway inhibitor and protein C. Studies have shown that
more than 80% of patients with severe sepsis had a baseline
protein C level below the lower limit of normal [9,16-18].
Plasma protein  C levels decrease early in patients who
develop severe sepsis, often before clinical symptoms appear,
and these levels remain low, gradually rising in patients who
recover and survive [18-21].
Numerous reports have examined the predictive value of
plasma protein C levels in sepsis. These reports confirm the
association between depressed protein C levels and the
increased likelihood of negative outcomes in sepsis, including
time on a ventilator, time in the ICU, development of shock
and increased mortality [17,19,22-33]. Protein C levels less
than approximately half the lower limit of normal are
associated with a much greater risk for death [19,29]. In a
recent multivariable analysis with ICU mortality as the depen-
dent variable [32], a minimum protein C concentration of less
than 45% was identified as an independent risk factor in
surgical ICU patients.
Data from previous studies of DrotAA also show a strong
association between very low protein C levels and mortality in
patients with severe sepsis. In the placebo arm of
PROWESS [9] no difference in mortality was identified
between patients with normal protein C levels (>80%
functional activity in the assay used) at baseline and those
with moderate protein C deficiency (41% to 80% activity). In
the former group, mortality was 5.7% at day 4 and 26.7% at
day 28, and in the latter group the corresponding percentages
were 5.5% and 24.9%, respectively. However, patients who
presented with severe protein C deficiency (activity levels half
the lower limit of normal or less [≤40%]) had a markedly
higher mortality both at day 4 (20%) and at day 28 (41.8%).
Even though severe protein C deficiency at baseline clearly
indicates a much greater risk for death, it is of note that there
is an additional approximate 20% mortality between days 4
and 28 in all three groups, independent of baseline protein C
levels. Based on this observation, additional analyses were
performed to investigate whether sequential measurements
of protein C levels would add further prognostic value. In
PROWESS, protein C levels were measured daily on study
days 1 to 7, 14 and 28. Figure 1 shows sequential protein C
measurements in PROWESS placebo patients grouped by
duration of survival [34]. In addition to the observation noted
above that very low protein C levels predict early death, it
was also demonstrated that survival beyond day 28 or
hospital discharge was associated with an early return of
endogenous protein C to above the lower limit of normal.
Inability to increase endogenous protein C level to the normal
range was indicative of poor outcome.
Effect of drotrecogin alfa (activated)
administration
It is important to note that the activity assay utilized to
measure protein C (the inactive zymogen) in the above
studies is not subject to significant interference by
therapeutic DrotAA (specifically, the assay reflects native
endogenous protein C and not infusion of APC).
In PROWESS [9] the observed relative risk reduction in
patients with protein C deficiency at baseline (≤80%) was
20%, whereas that in patients with normal protein C levels at
baseline (>80%) was 42%. There was no statistically signifi-
cant treatment-by-subgroup interaction observed based onPage 3 of 7
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subgroups defined by baseline protein C deficiency status
(P = 0.3338). This suggested that there was a treatment
benefit associated with DrotAA administration in severe
sepsis, irrespective of baseline protein C level. In an attempt
to gain a better understanding of these findings, the changes
in protein C levels from baseline to the end of study drug
infusion were analyzed.
Patients were classified as to whether they had normal
protein C levels at baseline or had a deficiency in protein C,
and whether they achieved normal protein C any time during
infusion or had below normal levels at any time during
infusion (Figure 2). In the group that was deficient in protein
C at baseline, DrotAA patients were significantly more likely
to improve to normal levels during infusion (P = 0.0001, by χ2
test); also, there was a trend (P = 0.14, by χ2 test) for more
placebo patients with normal protein C levels at baseline than
DrotAA patients to exhibit below normal levels. For patients
with below normal baseline protein C that remained below
normal during infusion, there was no significant difference in
28-day mortality rates (P = 0.24, by χ2 test) between
treatment groups. Similarly, for patients with normal baseline
protein C that remained normal during infusion, there was no
significant difference in 28-day mortality rates (P = 0.59, by
χ2 test) between treatment groups. Among those who
improved from below normal protein C levels to above normal
protein C levels, DrotAA patients tended to have a lower
mortality (P = 0.07, by χ2 test). DrotAA patients also had
lower mortality among those who had above normal levels
that fell below normal during infusion (P = 0.054). These
findings have the following implications. First, the DrotAA
treatment effect may be reflected, at least in part, by the
increase in numbers of patients presenting with normal
protein C levels at the end of infusion, who have generally low
mortality. Second, DrotAA benefits patients with normal
protein C levels at baseline because it reduces their
likelihood of becoming deficient or may help to restore levels
to normal by the end of infusion. Third, the benefit of DrotAA
treatment is largely confined to patients who are, or who will
become, protein C deficient.
Data from PROWESS and ENHANCE demonstrated that
higher end-of-infusion protein C levels are associated with
lower mortality (Figure 3). PROWESS also demonstrated
that, compared with placebo patients, fewer DrotAA patients
had severe protein C deficiency at the end of the infusion
(166 patients [19.5%] versus 217 patients [25.8%]), and a
greater number of DrotAA patients had normal protein C
levels at the end of the infusion (290 patients [34.1%] versus
211 patients [25.1%], P < 0.001). These findings were
observed even though the DrotAA group had a greater
number of patients with severe protein C deficiency at
baseline than did the placebo group (330 patients [38.8%]
versus 285 patients [33.9%]). The protein C levels in DrotAA
patients also rose more rapidly than did those in placebo
patients (Figure 4) and were significantly higher on each day
of the infusion period. There are a number of potential
explanations for the observed effect of DrotAA administration
on endogenous protein C levels. It could be due to
decreased consumption or degradation of endogenous
protein C as the consumptive coagulopathy is inhibited;
however, this may not be very relevant because the levels of
other coagulation factors such as antithrombin III or protein S
are not specifically increased with DrotAA treatment.
Alternatively, there might be a direct effect of protein C on
hepatic synthesis.
Although most patients in PROWESS and ENHANCE had
higher protein C levels at the end of the infusion, there
remained a substantial number of patients who were
protein C deficient despite treatment with DrotAA. Figure 5
shows the results of sequential protein C measurements in
patients treated with DrotAA. Analysis of protein C levels in
patients who died after completing the DrotAA infusion
(during study days 6 to 15) revealed that protein C levels
gradually increased during the infusion, but mean protein C
levels at the end of the infusion were less than three-quarters
of the lower limit of normal and decreased after the infusion
was completed. These patients may have benefited from a
longer duration of infusion. Patients who died during the
infusion were severely protein C deficient at baseline and
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Figure 1
Mean protein C activity levels over time for PROWESS placebo
patients classified according to timing of death [34]. Shown are means
and standard errors (SE) of protein C levels based on time of death of
PROWESS [9] drotrecogin alfa (activated) patients. Raw values with
no imputation are included. PROWESS, Recombinant Human
Activated Protein C Worldwide Evaluation in Severe Sepsis.Critical Care    Vol 11 Suppl 5 Vangerow et al.
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Figure 2
Change in protein C levels and 28-day mortality in PROWESS patients [9]. DrotAA, drotrecogin alfa (activated); N, total number of patients in each
group; PROWESS, Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis.
Figure 3
Mortality by end of infusion protein C level in PROWESS [9] and
ENHANCE [10]. Patients were included if they had a baseline protein
C measure. Day 4 protein C was classified as end of infusion. If the
protein C level on day 4 was not available, then last observation
carried forward values were used for classification. In this scale, >80%
is a normal protein C level and ≤40% is half or less of the lower limit of
normal. DrotAA, drotrecogin alfa (activated); ENHANCE, Extended
Evaluation of Recombinant Human Activated Protein C, drotrecogin
alfa (activated); N, total number of patients in each group; PROWESS,
Recombinant Human Activated Protein C Worldwide Evaluation in
Severe Sepsis.
Figure 4
Effect of DrotAA infusion on protein C levels in PROWESS [9]. Shown
are percentage changes in protein C level from baseline until day 7;
the data are the observed data with no imputation. DrotAA, drotrecogin
alfa (activated); PROWESS, Recombinant Human Activated Protein C
Worldwide Evaluation in Severe Sepsis.exhibited no increase in protein C level during the infusion.
These patients would not have had the opportunity to benefit
from a longer infusion duration alone, but they may have
benefited from an increased dose of DrotAA together,
perhaps, with a longer infusion. Such hypotheses have been
incorporated into the RESPOND study design.
The RESPOND study
RESPOND, a phase II double blind study aiming to recruit
488 patients, is the first step toward exploring the use of
endogenous protein C level as a biomarker to guide the
administration (both dosage and duration) of DrotAA. The
study is organized into three periods: pretreatment, treatment
and post-treatment. To be eligible for inclusion in the study,
patients must have multiple organ dysfunction and protein C
deficiency (protein C level less than the lower limit of normal).
Protein C levels will be measured at each investigative site
using a point-of-care immunoassay or a standard laboratory
analyzer using an activity-based diagnostic kit.
The pretreatment period starts with the onset of multiple
organ dysfunction (two or more sepsis-induced organ dys-
functions). After the onset of the second sepsis-induced
organ dysfunction, a maximum of 24 hours is allowed to
assess patient eligibility for inclusion in the study, obtain
informed consent, perform baseline evaluations and deter-
mine patient treatment assignment. No more than 36 hours
can elapse between the onset of the first sepsis-induced
organ dysfunction and the start of the treatment period.
The treatment period begins with a common therapy lead-in,
in which all patients will receive DrotAA at a dose of 24 μg/kg
per hour for 24 hours. The rationale for this is underpinned by
the observations from PROWESS that approximately one-
third of patients who had severe protein C deficiency at
baseline were no longer severely deficient after 24 hours of
DrotAA therapy, and that approximately one-quarter of
patients who were not severely deficient at baseline were
deficient at 24 hours, despite DrotAA treatment. This allows
an initial assessment of response to standard dose therapy
(24 μg/kg per hour DrotAA).
After the 24-hour lead-in period, patients will receive the
treatment that they were randomly assigned to (at baseline),
either standard or alternative therapy. The alternative therapy
received will depend on whether the patient’s protein C level
at the end of the lead-in period is less or greater than half the
lower limit of normal, as demonstrated in Figure 1.
All patients assigned to standard therapy will receive an
additional 72-hour infusion of DrotAA 24 μg/kg per hour (for
a total infusion duration of 96 hours).
Patients assigned to receive alternative therapy of variable
duration (the alternative therapy-variable duration arm), who
have moderate protein C deficiency at the end of the lead-in
period, will receive DrotAA 24 μg/kg per hour for an
additional 24 to 144 hours. The treatment will be continued
until two consecutive protein C levels are greater than or
equal to the lower limit of normal, or the patient has received
DrotAA for a total infusion duration of 168 hours. Based on
results from PROWESS, this group of patients is anticipated
to have a relatively low risk for early death (6.3% at day 5 and
20.0% at day 28, Figure 5), and therefore they will only be
exposed to variable duration of DrotAA infusion and not a
higher dose.
Patients assigned to alternative therapy at higher dose and of
variable duration (the alternative therapy-higher dose/variable
duration arm), who have severe protein C deficiency at the
end of the lead-in period, will receive a variable duration of
DrotAA infusion (as described above for the alternative
therapy-variable duration arm) and a higher dose of DrotAA
(30 μg/kg per hour up to 48 μg/kg per hour). Based on results
from PROWESS this group is anticipated to have a relatively
high risk for early death (18.8% at day 5 and 33.6% at day 28,
Figure 5), and therefore this group will be exposed to both
higher doses and a variable duration of DrotAA infusion.
Each patient’s infusion will be administered at a single
infusion rate. A data monitoring committee will review safety
data from the lower dose groups before enrolling patients in
the next higher dose group. Figure 6 illustrates the different
arms of the trial after completion of the common lead-in
period, and shows the outcomes of corresponding
PROWESS patients, indicating lower mortality among
Available online http://ccforum.com/content/11/S5/S4
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Figure 5
Mean protein C activity over time for selected PROWESS DrotAA
patients classified by timing of death. Presented are means and
standard errors (SE) of protein C levels based on time of death of
PROWESS [9] DrotAA patients. Raw values with no imputation are
included. Note that not all groups are shown. DrotAA, drotrecogin alfa
(activated); PROWESS, Recombinant Human Activated Protein C
Worldwide Evaluation in Severe Sepsis.patients in whom protein C levels normalized by the end of
the infusion period.
Shrouded infusion bags will be provided to the ICU by an
unblinded pharmacist, who will make up a DrotAA or normal
saline infusion depending on the most recent protein C level
and the stage of the study. This will ensure that the
investigative staff will remain blinded to the study treatment.
RESPOND seeks to demonstrate that ‘alternative therapy’
results in a greater increase in protein C levels than ‘standard
therapy’ and, importantly, to provide appropriate safety and
efficacy data to determine the most appropriate aspects of
alternative therapy to incorporate into possible future studies. If
RESPOND is successful, then a larger phase 3 study will be
required to demonstrate whether improved protein C levels
resulting from alternative therapy are also associated with
statistically significant mortality reductions as compared with
standard therapy. The ultimate aim of RESPOND and potential
following studies is to establish serial plasma protein C
measurements as a biomarker that will aid in the identification
of those patients with severe sepsis who are most likely to
benefit from DrotAA, that will enable adjustment of DrotAA
therapy to the needs of individual patients (specifically, the
possibility to use a higher dose and to adjust the infusion
duration), and that will provide guidance to the clinician
regarding whether the patient is responding to DrotAA therapy.
Conclusion
The future of medicine might be individualized therapy based
on biomarkers or gene profiles. Until then, RESPOND
represents the first step toward tailored sepsis treatment.
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